Stocks/SLGL

Create a free account to see ACCE Scores

Sign up for free to unlock scores, score breakdowns, and stock analysis.

SLGL

↓ PDF (Pro)
Sol-Gel Technologies Ltd. Ordinary Shares
HealthcareBiotechnologyIsraelNASDAQ
$70.90
-3.89%today
MKT CAP
$230M
-7.4% · 1Y
Earnings History
-
-1.9%
-371.8%
Q2 '25
Q3 '25
Q4 '25
Analyst Targets
Current price
$70.90
Low
$110.00
Analyst Mean
$110.00
High
$110.00
1 analystNone
Full Financials
Trailing P/E-
Forward P/E-10.2x
EV/EBITDA-
Price/Sales-
Dividend Yield-
Revenue Growth YoY-
Earnings Growth YoY-
Revenue Growth QoQ+74.0%
5y Revenue CAGR+70.9%
5y Earnings CAGR-
Gross Margin-
Operating Margin-
Net Margin-
ROE-
Debt / Equity-
Free Cash Flow-
Insider Ownership60.1%
Institutional Ownership35.3%
Short % of Float1.82%
Days to Cover0.3d
1 Week+7.5%
1 Month-
3 Months-
6 Months-
YTD-
1 Year-
3 Years-
5 Years-
vs 50-day SMA-
vs 200-day SMA-
vs 52w High-
vs 52w Low-
Top Holders
HolderType% HeldValueΔ SharesAs of
Opaleye Management Inc.institution16.15%$0.03B+121.51%2025-12-31
Phoenix Financial Ltd.institution7.77%$0.02B+0.00%2025-12-31
Yelin Lapidot Holdings Management Ltd.institution0.63%$0.00B+0.00%2026-03-31
Menora Mivtachim Holdings Ltd.institution0.27%$0.00B+0.00%2025-12-31
Citadel Advisors Llcinstitution0.22%$0.00B+100.00%2025-12-31
Raymond James Financial, Inc.institution0.20%$0.00B+100.00%2025-12-31
Morgan Stanleyinstitution0.17%$0.00B+7.31%2025-12-31
Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fundfund0.05%$0.00B+0.00%2026-02-28
Blackrock Inc.institution0.03%$0.00B+209.42%2025-12-31
UBS Group AGinstitution0.02%$0.00B-45.48%2026-03-31
Steward Partners Investment Advisory, LLCinstitution0.01%$0.00B+0.00%2025-12-31
TickerCapScoreP/EFwd P/EEV/EBITDAROEGrossD/EDiv
PTGX
Protagonist Therapeutics Inc. Common Stock
$6.6B5------0.00%
CELC
Celcuity Inc. Common Stock
$6.7B5------0.00%
ACLX
Arcellx Inc. Common Stock
$6.7B5-------
KYMR
Kymera Therapeutics Inc. Common Stock
$7.0B-----27.1%0%5.230.00%
TECH
Bio-Techne Corp Common Stock
$7.1B3672.724.4----63.00%
HALO
Halozyme Therapeutics Inc. Common Stock
$7.9B7325.56.6----0.00%
Peers selected by sector + industry + nearest market cap. Best in column highlighted green, worst red.
Unlock Full Financials
Growth metrics, valuation multiples, and profitability ratios on Starter+.
Upgrade from $15/mo →
Growth73Value58Quality82Momentum61Total5
Score breakdown on Starter+
Upgrade →
Score History (90d)
Pro onlyUpgrade →
Updated 5/8/2026
Recent Alerts
No alerts yet for SLGL.
Want deep analysis?
This stock isn't in the ACCE researched universe. Browse 300+ stocks with full thesis, scores, and financial models.
Browse ACCE Indices →
Get the ACCE weekly digest
Index returns, picks recap, score movers - every Sunday. No fluff.